Handelsavisen
prelaunch
Companies Healthcare CTE.AX
CT
CTE.AX ASX Healthcare Facilities & Services

Cryosite Ltd

A$1,06
Open in Charts → Attach watcher ⌖
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Cryosite Ltd provides cryogenic storage and logistics solutions for the biotechnology and healthcare industries, primarily generating revenue through storage fees and service contracts.

Business. Cryosite Ltd (CTE.AX) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in Australia, with its primary listing on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning CTE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to CTE.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Cryosite Ltd (CTE.AX) is a healthcare services and equipment company primarily engaged in biotechnology activities within the healthcare facilities and services industry. The firm operates on a service-revenue model and is headquartered in Australia, with its primary listing on the Australian Securities Exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    Cryosite operates with a fully diluted share count of 48.81 million shares, with no additional shares outstanding in the diluted count, indicating no dilution from stock options or convertible instruments. However, the company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which raises uncertainty about its short-term financial flexibility.

    Profitability and return metrics are not available for Cryosite, as the valuation snapshot does not include key performance indicators such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to assess the company's efficiency and returns relative to industry peers or the preferred metrics outlined in the industry configuration.

    Cryosite's revenue is primarily derived from its core cryogenic storage and logistics services, with no disclosed segment or geographic breakdown in the available data. This lack of segmentation detail limits the ability to assess revenue concentration or geographic diversification.

    The company's growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Without historical revenue data or forward-looking statements, it is difficult to determine whether the company is in a growth or contraction phase.

    Risk factors for Cryosite include the inability to assess liquidity risk, which could impact its ability to meet short-term obligations. The company is also exposed to dilution risk, though it is currently rated as low. No specific dilution sources or adjustments have been identified in the valuation data.

    Recent events or filings have not been disclosed in the available data, which limits the ability to assess any material developments or strategic shifts in the company's operations or financial position.

    Key takeaways
    • Cryosite operates in the Healthcare Facilities & Services industry, providing cryogenic storage and logistics solutions.
    • The company's liquidity position could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
    • Profitability and return metrics are not available, making it difficult to evaluate performance relative to industry benchmarks.
    • No segment or geographic revenue breakdown is provided, limiting visibility into revenue concentration and diversification.
    • Growth trajectory and forward-looking guidance are not disclosed, making it challenging to assess future performance.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation FY

    Market price
    A$1,06
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Cryosite Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    CTE.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage